Programmed Cell Death — Pathways, Regulation & Disease
A complete guide to the biology of programmed cell death — from the morphological hallmarks defined by Kerr, Wyllie, and Currie in 1972 through the intrinsic and extrinsic caspase cascades, Bcl-2 family proteins, the apoptosome, death-inducing signalling complex (DISC), p53-mediated apoptotic signalling, efferocytosis, developmental and immunological roles, and the dysregulation of apoptotic pathways in cancer, neurodegeneration, and autoimmune disease — to the therapeutic targeting of apoptotic machinery in clinical oncology.
Every day, the human body deletes approximately 50–70 billion of its own cells through an orderly molecular suicide programme — a process so precisely executed that it leaves no inflammatory trace, no cellular debris, and no disruption to surrounding tissue. This is apoptosis: the cell’s built-in demolition protocol, as fundamental to life as cell division and as carefully regulated as DNA replication. Without it, embryos cannot form functional organs, immune systems cannot eliminate self-reactive lymphocytes, tumours cannot be suppressed, and cells damaged beyond repair cannot be safely disposed of. With too much of it, neurons die in their millions in Alzheimer’s, cardiac tissue is lost after heart attack, and immune cells are depleted in HIV infection. Understanding apoptosis is not merely an academic exercise — it is the foundation of modern cancer biology, drug discovery, and regenerative medicine.
What Apoptosis Is — Definition, History, and Biological Significance
The word apoptosis (pronounced a-po-TOE-sis) derives from the Greek for “falling off” — evoking leaves dropping from a tree in autumn, or petals falling from a flower. The term was introduced in 1972 in a landmark paper by John Kerr, Andrew Wyllie, and Alastair Currie in the British Journal of Cancer, describing a morphologically distinct and physiologically regulated form of cell death that they distinguished clearly from the passive, uncontrolled cell death of necrosis. Their insight — that cells could execute an active, genetically controlled self-destruction programme — was ahead of its time: it took another two decades and the molecular biology revolution for the full mechanistic picture to emerge.
The molecular foundations of apoptosis were primarily worked out in the nematode Caenorhabditis elegans, where the complete cell lineage is known and invariant: exactly 131 of the 1,090 somatic cells generated during development undergo programmed cell death at precise, predetermined times. Sydney Brenner, John Sulston, and Robert Horvitz — who shared the 2002 Nobel Prize — identified the core apoptosis genes in C. elegans: ced-3 (encoding a cysteine protease later recognised as the founding caspase), ced-4 (homologue of mammalian APAF-1), and ced-9 (homologue of BCL-2), establishing the conserved three-gene logic of cell death regulation that operates from worms to humans. As comprehensively reviewed in the foundational PMC reference on apoptosis as programmed cell death, this conserved pathway spans billions of years of evolutionary history, underscoring its essential role in multicellular life.
Homeostasis — Tissue Balance
Apoptosis balances cell proliferation to maintain tissue size and organisation. In self-renewing tissues (intestinal epithelium, haematopoietic system, skin), millions of cells are created by stem cell division every hour — apoptosis at the end of each cell’s functional lifespan prevents uncontrolled tissue overgrowth. The rate of apoptosis and proliferation are precisely co-regulated by survival signals (growth factors, adhesion molecules) and death signals, both of which act on the Bcl-2 family network.
Development — Sculpting Organs
Embryonic morphogenesis relies on precisely positioned apoptosis to sculpt three-dimensional structures from cell masses. The fingers and toes form when apoptosis eliminates interdigital webbing; the hollow lumen of the vertebrate heart forms from a solid cell mass through apoptosis; synapse pruning in the developing brain removes supernumerary neurons and connections. The absence of apoptosis in the correct developmental context produces syndactyly, cardiac defects, and neurological abnormalities.
Immunity — Eliminating Threats
The immune system depends on apoptosis at multiple levels: deletion of autoreactive T and B lymphocytes in the thymus and bone marrow prevents autoimmunity; cytotoxic T lymphocytes and NK cells kill target cells (virus-infected, cancer cells) by inducing apoptosis through perforin/granzyme delivery and Fas-FasL interactions; apoptosis of activated lymphocytes at the end of an immune response (activation-induced cell death, AICD) contracts the immune response to avoid chronic activation and tissue damage.
Morphological and Biochemical Hallmarks of Apoptosis
Apoptosis has a stereotyped, recognisable appearance that distinguishes it from other forms of cell death. These morphological features are the consequence of specific biochemical events — primarily caspase-mediated substrate cleavage — and their recognition in histological sections, electron micrographs, or live-cell imaging is the foundational evidence that apoptosis has occurred. Understanding what these features look like and why they occur is essential for interpreting experimental and pathological data correctly.
Sequence of Morphological Events in an Apoptosing Cell
Cell shrinkage and condensation: One of the earliest visible changes — the cell reduces in volume by approximately 30–50%, pulling away from neighbouring cells and losing the regular architecture of the healthy cell. Caspase cleavage of cytoskeletal proteins (actin, vimentin, gelsolin) and water efflux through regulated ion channels drives this compaction. Under light microscopy, apoptotic cells stain more intensely with haematoxylin (eosinophilic condensed cytoplasm) compared to normal neighbours.
Chromatin condensation (pyknosis) and nuclear fragmentation (karyorrhexis): The hallmark nuclear changes begin with compaction of chromatin against the nuclear envelope, forming dense crescents visible in electron micrographs. Caspase-activated DNase (CAD) — released when caspase-3 cleaves its inhibitor ICAD — cleaves genomic DNA at internucleosomal linker regions (between nucleosomes), generating ~180 bp laddering fragments. This produces the classic “DNA ladder” on gel electrophoresis — a diagnostic biochemical marker of apoptosis. Nuclear lamins are cleaved by caspase-6, collapsing the nuclear scaffold and causing the nucleus to fragment into multiple chromatin-dense pieces.
Membrane blebbing: The plasma membrane forms dynamic outward bulges (blebs) driven by acto-myosin contraction. Caspase-3 activates ROCK1 kinase (by cleaving its auto-inhibitory domain), which phosphorylates myosin light chain, generating the contractile force powering blebbing. Blebs do not rupture; the membrane remains intact. Phosphatidylserine (PS) exposure on the outer membrane leaflet — normally confined to the inner leaflet — occurs through caspase-mediated inhibition of flippase enzymes and activation of scramblase, and is the primary “eat-me” signal recognised by phagocytes.
Apoptotic body formation and phagocytosis: The cell fragments into membrane-enclosed structures called apoptotic bodies (1–5 µm diameter), each containing condensed organelles, nuclear fragments, and intact plasma membrane. Apoptotic bodies display “eat-me” signals (PS, calreticulin, thrombospondin bridging molecules) and emit “find-me” chemoattractant signals (ATP, UTP released through pannexin-1 channels; lysophosphatidylcholine; fractalkine). Neighbouring cells or resident macrophages rapidly engulf them through efferocytosis within minutes to hours — before any membrane rupture can release inflammatory contents.
The Intrinsic (Mitochondrial) Pathway — Responding to Internal Stress
The intrinsic pathway is the primary route to apoptosis in mammalian cells responding to cellular stress, DNA damage, growth factor withdrawal, and oncogenic pressure. It is named for its initiation from within the cell — contrasting with the externally triggered extrinsic pathway — and for the central role of the mitochondria as the commitment point from which it is nearly impossible to retreat. Its discovery and elucidation — driven by Xiaodong Wang’s identification of cytochrome c as an apoptotic activator in 1996 and subsequent work from Wang, Bharat Bhola, and Junying Yuan laboratories — transformed understanding of both apoptosis and mitochondrial biology.
Apoptotic Signals Converge on BH3-Only Proteins
Internal stress stimuli activate specific BH3-only proteins — the sentinels of the intrinsic pathway. DNA double-strand breaks activate ATM/Chk2 which phosphorylates and stabilises p53, inducing transcription of PUMA and NOXA. Cytokine withdrawal activates BIM (inactivation of the survival kinase ERK or AKT releases BIM from sequestration). Hypoxia induces BNIP3L. ER stress activates PUMA and BIK through the PERK/ATF4/CHOP axis. Oncogenic signalling activates ARF which stabilises p53. Each BH3-only protein senses a specific upstream stress signal and feeds that information into the Bcl-2 family regulatory network at the mitochondria.
BH3-Only Proteins Activate BAX and BAK (Effectors)
BH3-only proteins activate apoptosis through two complementary mechanisms. Direct activators (BIM, BID, PUMA) bind directly to BAX and BAK, triggering conformational change and their activation. Sensitisers/derepressors (BAD, NOXA, BMF, HRK) bind and neutralise anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1), freeing BAX and BAK from their suppression. The “indirect activation” model holds that anti-apoptotic proteins constitutively suppress BAX/BAK activation; sensitiser BH3-only proteins displace anti-apoptotic proteins from BAX/BAK complexes, releasing them for activation by constitutively present direct activators. The balance between these competing interactions determines whether cells survive or die.
BAX/BAK Oligomerisation and MOMP
Activated BAX (which translocates from cytosol to the mitochondrial outer membrane upon activation) and BAK (which is constitutively mitochondria-associated) undergo conformational changes exposing their BH3 domain and C-terminal membrane anchor. They oligomerise — forming first dimers, then higher-order oligomers — and insert into the mitochondrial outer membrane, forming proteolipid pores. These pores permeabilise the outer membrane (MOMP — mitochondrial outer membrane permeabilisation), releasing pro-apoptotic proteins from the intermembrane space. MOMP is the critical point of no return in intrinsic apoptosis: once the majority of mitochondria in a cell undergo MOMP, execution of apoptosis is essentially guaranteed regardless of subsequent events.
Cytochrome c and SMAC Release from Mitochondria
MOMP releases the contents of the mitochondrial intermembrane space into the cytosol. The two most critical are: cytochrome c — a small haem protein normally embedded in the inner mitochondrial membrane as an electron carrier in the respiratory chain — which becomes the key activator of the apoptosome; and SMAC/DIABLO (second mitochondria-derived activator of caspases) — which antagonises IAP proteins that otherwise inhibit caspases. Additional released factors include HTRA2/OMI (a serine protease that also antagonises IAPs) and AIF (apoptosis-inducing factor — which translocates to the nucleus and causes caspase-independent DNA fragmentation in a parallel apoptotic execution pathway, particularly important in neurons).
Apoptosome Assembly and Caspase-9 Activation
Released cytochrome c binds APAF-1 in the cytosol, inducing a conformational change in APAF-1 that exposes its CARD domain. Seven cytochrome c:APAF-1 complexes assemble into the wheel-shaped apoptosome heptamer. The seven CARD domains project from the wheel, recruiting procaspase-9 through CARD-CARD interactions. Proximity and oligomerisation activate procaspase-9 (without requiring cleavage) in the proximity-induced dimerisation model. Active caspase-9 within the apoptosome cleaves and activates executioner caspases-3 and -7 — which then cleave hundreds of cellular substrates to systematically dismantle the cell.
The Bcl-2 Family — Molecular Switches Between Life and Death
The Bcl-2 (B-cell lymphoma 2) family is the central regulatory network of the intrinsic apoptosis pathway — a large family of structurally related proteins that collectively determine whether a cell lives or dies in response to stress. The family is defined by the presence of one or more Bcl-2 homology (BH) domains (BH1–BH4), which mediate protein-protein interactions through a hydrophobic groove, and most members are associated with or targeted to the mitochondrial outer membrane. The family divides into three functional subgroups with opposing roles.
BCL-2, BCL-XL, MCL-1, BCL-W, A1
The pro-survival members all contain four BH domains (BH1–BH4) forming a hydrophobic groove that engages the BH3 helix of pro-apoptotic proteins. They suppress apoptosis by sequestering activated BAX/BAK and by binding BH3-only proteins. BCL-2 was the first identified — discovered at the t(14;18) chromosomal breakpoint in follicular lymphoma in 1985, where it is fused to the immunoglobulin heavy chain locus and constitutively overexpressed. BCL-XL is the predominant anti-apoptotic protein in most non-haematopoietic cells; MCL-1 has a short half-life (rapid turnover) making it sensitive to translational and proteasomal regulation. Each family member has distinct binding selectivity for different BH3-only proteins — a key feature for selective therapeutic targeting.
BAX, BAK, BOK
The effector proteins directly execute MOMP. BAX (Bcl-2-associated X protein) resides predominantly in the cytosol as a monomeric protein in healthy cells; upon activation by BIM/BID it undergoes conformational changes (N-terminal unmasking, C-terminal helix 9 retraction from the hydrophobic groove) allowing membrane insertion and oligomerisation. BAK is constitutively associated with the mitochondrial outer membrane, held inactive by MCL-1 and BCL-XL binding; BIM and BID displace these and allow BAK activation. BAX/BAK double knockout cells are completely resistant to intrinsic apoptosis induced by any stimulus. BOK may also contribute to MOMP in specific contexts (ER-associated), particularly in response to ER stress.
BIM, PUMA, NOXA, BID, BAD, BMF, HRK, BIK
The BH3-only proteins contain only the BH3 domain — the “death domain” of the Bcl-2 family — and serve as tissue- and stress-specific apoptotic triggers. They activate apoptosis either by directly activating BAX/BAK (direct activators: BIM, cleaved BID [tBID], and debatably PUMA) or by neutralising anti-apoptotic proteins (sensitisers: BAD targets BCL-2/BCL-XL; NOXA targets MCL-1; BMF and HRK have broader selectivity). BH3-only proteins are regulated at every level — transcription (PUMA, NOXA by p53), translation (BIM), post-translational modification (BIM phosphorylation by ERK promotes proteasomal degradation; BAD phosphorylation by AKT promotes sequestration by 14-3-3 proteins), and by proteolytic activation (BID cleavage to tBID by caspase-8).
Predicting Apoptotic Dependency in Cancer Cells
BH3 profiling (developed by Anthony Letai) is a functional assay measuring the apoptotic sensitivity of cancer cells by exposing them to BH3 peptides from specific BH3-only proteins and measuring mitochondrial cytochrome c release. “Primed” cells — with much of their BAX/BAK already bound and suppressed by anti-apoptotic proteins (high baseline stress) — are near the apoptotic threshold and highly sensitive to BH3 mimetic drugs. “Unprimed” cells tolerate additional stress. BH3 profiling has been used clinically to predict which patients’ cancers will respond to venetoclax (BCL-2 inhibitor) — one of the few examples of functional predictive biomarkers in oncology. BH3 profiling identifies which anti-apoptotic protein is responsible for priming (BCL-2, BCL-XL, or MCL-1), directly informing drug selection.
The First Oncogene That Inhibits Death
The discovery of BCL-2 at the t(14;18) translocation breakpoint in follicular lymphoma established the paradigm that cancer can arise not just by accelerating cell growth but by blocking cell death. The translocation places BCL-2 under immunoglobulin heavy chain enhancer control, causing constitutive overexpression in B cells. These cells accumulate because they cannot die — BCL-2 overexpression extends their lifespan far beyond normal, giving time for secondary mutations (MYC translocation in transformation to diffuse large B-cell lymphoma; BRAF mutation). This observation was the conceptual origin of anti-apoptotic BCL-2 as a cancer drug target, ultimately leading to venetoclax.
Short Half-Life, Broad Cancer Relevance
MCL-1 is the most frequently amplified gene in human cancer (chromosome 1q21, amplified in 10–20% of all tumours) and is the dominant survival factor in many haematological malignancies (AML, multiple myeloma), solid tumours, and in resistance to BCL-2/BCL-XL inhibitors. Its short half-life (~30–90 minutes) makes it sensitive to translational inhibition (ribociclib, homoharringtonine), proteasomal inhibitors, and direct BH3 mimetics (AMG-176, S63845, AZD5991). MCL-1 selectivity for NOXA (which exclusively neutralises MCL-1) explains why NOXA is less effective than BIM or PUMA at inducing apoptosis in MCL-1-dependent cells without co-treatment with BCL-2/BCL-XL inhibitors.
From Dormant Cytosol to Pore-Forming Machine
Inactive cytosolic BAX adopts a closed, globular conformation in which its C-terminal helix 9 (membrane anchor) is tucked into the canonical BH3-binding groove, and its N-terminal BH4-containing helix 1 shields the activation surface. Direct activator BH3 peptides (from BIM/BID) bind a non-canonical surface (“trigger site”) on BAX helix 1, inducing allosteric conformational changes: helix 9 exits the groove, the N-terminus unfolds (detected by the conformation-specific 6A7 antibody — a key assay for BAX activation), and the BH3 domain is exposed for symmetric BH3:groove dimerisation. Dimers then assemble into higher oligomers that form proteolipid pores. The exact pore architecture and lipid composition remain active research questions, but lipidic toroidal pores and protein-lined barrel structures have been proposed.
Survival Signals Beyond Cancer
Anti-apoptotic Bcl-2 family members are not pathological proteins — they are essential survival factors in normal physiology, receiving and interpreting survival signals (growth factors, adhesion, cytokines) through regulation of BH3-only protein activity. BCL-2 maintains long-lived cells (memory lymphocytes, plasma cells, neurons, haematopoietic stem cells); BCL-XL preserves platelets and mature erythrocytes; MCL-1 is required for stem cell maintenance and early embryonic development. This normal physiological role explains the on-target toxicities of BH3 mimetics: venetoclax causes neutropenia and thrombocytopenia; navitoclax (BCL-XL inhibitor) causes platelet destruction by inducing apoptosis of BCL-XL-dependent platelets.
MOMP — the Commitment Point of Intrinsic Apoptosis
Mitochondrial outer membrane permeabilisation (MOMP) is the critical, near-irreversible threshold event in the intrinsic apoptosis pathway — the point at which a cell’s commitment to die transitions from conditional to essentially certain. Understanding MOMP — its mechanism, its regulation, and what happens to cells that experience incomplete MOMP — is one of the most active and clinically important areas of cell death biology.
What Happens During MOMP
BAX and BAK oligomers form proteolipid pores in the mitochondrial outer membrane large enough to allow passage of large proteins (cytochrome c is ~12 kDa; SMAC is ~27 kDa as a dimer). The pores are distinct from the permeability transition pore (PTP) of the inner membrane — MOMP can occur without inner membrane permeability transition. Release of intermembrane space proteins begins within minutes of BAX/BAK activation and is typically complete within 30–60 minutes in individual mitochondria. A key concept is “all-or-none” MOMP within individual mitochondria — each mitochondrion either undergoes complete permeabilisation or not at all, and the population of mitochondria in a single cell undergoes MOMP asynchronously, but activation spreads wave-like through the cell driven by autocatalytic caspase activation and reactive oxygen species.
A recently described phenomenon — minority MOMP — occurs when a small subset of mitochondria undergo MOMP while the majority do not. This can generate sublethal caspase activation sufficient for DNA damage (mutagenesis) without causing apoptosis. Minority MOMP has been implicated in genome instability in cancer cells that survive near-apoptotic stress — contributing to tumour evolution.
Anastasis — Reversal of MOMP
The concept that apoptosis is irreversible after MOMP has been challenged by the discovery of anastasis (Greek: “rising to life”) — the survival and recovery of cells that have activated caspases, released cytochrome c, and undergone early apoptotic morphological changes, when apoptotic stimuli are removed. Anastatic cells survive, divide, and maintain functional DNA — but may carry mutations and genomic instability as a consequence of caspase-activated DNase activity during the near-death experience. Anastasis has been documented in cultured cells exposed to transient ethanol, heat shock, or pro-apoptotic signalling, and may occur in vivo following transient ischaemia. Its clinical significance — as a potential contributor to post-cancer treatment relapse and genomic diversity — is an active area of investigation that challenges long-held assumptions about apoptosis irreversibility.
The Apoptosome — Caspase-9 Activation Platform
Apoptosome Architecture, Assembly, and Function
The apoptosome is a cytosolic heptameric (~1.4 MDa) complex formed after MOMP that serves as the activation platform for caspase-9 — the initiator caspase of the intrinsic pathway. Its assembly requires three components: cytochrome c (released during MOMP), APAF-1 (apoptotic protease-activating factor 1), and procaspase-9. APAF-1 is a large (~130 kDa) scaffold protein containing three domains: an N-terminal CARD (caspase recruitment domain) that recruits procaspase-9; a central NOD/NACHT domain that binds nucleotides and mediates APAF-1 oligomerisation; and C-terminal WD40 repeats that bind cytochrome c and in its absence fold back to autoinhibit the NOD domain.
Assembly proceeds as follows: cytochrome c binds the WD40 repeats of APAF-1, inducing conformational change that releases autoinhibition of the NOD domain. Freed APAF-1 binds dATP/ATP at the NOD domain; hydrolysis to ADP drives further conformational change exposing the CARD domain. Seven activated APAF-1 molecules assemble into a wheel-shaped heptameric platform via their NOD domains. The seven CARD domains project apically, forming a disc that recruits procaspase-9 via CARD-CARD homotypic interactions. This proximity induces procaspase-9 dimerisation and activation (without requiring cleavage — “proximity-induced dimerisation” model). Active caspase-9 within the apoptosome is more active than free caspase-9 — it is protected from dissociation and re-inhibition by XIAP, and the holoenzyme generates a positive feedback by cleaving procaspase-9 at the inter-subunit linker.
The activated apoptosome cleaves procaspase-3 and -7 into their active forms. Caspase-3 then reciprocally cleaves and activates further procaspase-9, establishing a self-amplifying activation loop. XIAP inhibits this cascade by binding the IBM (IAP-binding motif) of processed caspase-9, blocking its active site. SMAC/DIABLO antagonises XIAP by competing for the same BIR3 domain interaction, ensuring that once MOMP occurs, the caspase cascade proceeds to completion in a digital switch-like manner. Calcium and neutral pH favour apoptosome assembly; acidic pH (as in acidotic tissues) and cytochrome c sequestration by HSPB1/2 (heat shock proteins) can inhibit it — providing a potential link between physiological conditions and apoptosis sensitivity.
The Extrinsic (Death Receptor) Pathway — External Death Signals
The extrinsic pathway is initiated from outside the cell — by death ligands binding surface death receptors that belong to the tumour necrosis factor receptor (TNFR) superfamily. It is the primary mechanism by which the immune system kills virus-infected cells, tumour cells, and autoimmune lymphocytes, and by which TNF mediates inflammatory cytotoxicity. The pathway was elucidated in the 1990s through the identification of Fas/CD95, TRAIL receptors, and TNFR1, and the characterisation of the death-inducing signalling complex (DISC) by Henning Walczak and Klaus-Michael Debatin.
Fas (CD95) — Immune Homeostasis
Fas (CD95/APO-1) and its ligand FasL (CD95L) regulate immune contraction and cytotoxic lymphocyte killing. FasL is expressed on activated T cells, NK cells, and in immune-privileged sites (cornea, testis, brain). Fas is expressed widely. FasL/Fas interaction drives DISC formation and apoptosis. Mutations in Fas or FasL cause autoimmune lymphoproliferative syndrome (ALPS) — demonstrating the essential role of Fas-mediated apoptosis in terminating immune responses and deleting autoreactive lymphocytes.
TRAIL Receptors — Cancer-Selective Death
TRAIL (TNF-related apoptosis-inducing ligand) signals through death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), and interestingly preferentially kills transformed and cancer cells while sparing most normal cells — though the molecular basis of this selectivity is incompletely understood. This selectivity made TRAIL and DR4/DR5 agonists attractive cancer drug targets. Dulanermin (recombinant TRAIL) and agonistic DR5 antibodies have been tested in clinical trials, though efficacy as single agents has been limited, driving interest in combination with chemotherapy, HDAC inhibitors, or BCL-2 antagonists that sensitise cancer cells to TRAIL.
TNF/TNFR1 — Death or Survival?
TNF binding to TNFR1 initiates a complex signalling choice between survival (NF-κB activation) and death (caspase-8 activation). The initial complex I (RIPK1, TRADD, TRAF2/5, cIAP1/2) activates NF-κB through RIPK1 ubiquitination. Internalisation converts this to complex IIa (FADD, caspase-8) or complex IIb/necrosome (RIPK1, RIPK3, MLKL) leading to apoptosis or necroptosis respectively. Cell fate depends on cIAP levels, NF-κB activity, and cFLIP expression, making TNFR1 signalling context-dependent in a way that is clinically relevant for inflammatory disease therapy.
DISC Formation and Caspase-8 Activation
The death-inducing signalling complex (DISC) is the activation platform for the extrinsic pathway — the molecular machine that initiates the caspase cascade in response to death receptor ligation. Its formation is tightly regulated by cFLIP proteins that can either promote or inhibit caspase-8 activation depending on their isoform and stoichiometry.
DISC ASSEMBLY (Fas pathway): Step 1: FasL trimerises → crosslinks three Fas receptors Step 2: Fas death domains (DD) recruit FADD death domain (DD) Step 3: FADD DED recruits procaspase-8 and -10 DEDs Step 4: Procaspase-8 undergoes proximity-induced dimerisation → auto-cleavage Step 5: Active caspase-8 released from DISC into cytosol cFLIP REGULATION: cFLIP-L (long): Heterodimer with caspase-8 at DISC → reduced but maintained caspase-8 activity Low levels: pro-apoptotic; High levels: anti-apoptotic (competition) cFLIP-S (short): Dominant-negative — blocks caspase-8 activity entirely at DISC cFLIP regulated by: NF-κB (survival signal), TRAIL/chemotherapy (downregulate) TYPE I vs TYPE II CELL FATE: Type I cells (thymocytes, some lymphocytes): Large DISC → High caspase-8 → Direct caspase-3 activation → Execution BCL-2 overexpression CANNOT block apoptosis in type I cells Type II cells (hepatocytes, pancreatic β-cells, most solid tumour cells): Small DISC → Low caspase-8 → BID cleavage → tBID → BAX/BAK → Amplification BCL-2 overexpression CAN block apoptosis in type II cells (blocks amplification loop) Clinical significance: BCL-2/XL inhibitors sensitise type II cancer cells to death receptor ligands
The Caspase Cascade — Initiators, Executioners, and Their Substrates
Caspases are the molecular scissors of apoptosis — a family of 14 cysteine-aspartic proteases (in humans) that cleave hundreds of cellular substrates at specific aspartate-containing recognition sequences, systematically dismantling the cell. Their biology — from zymogen activation to substrate specificity to IAP-mediated inhibition — determines the efficiency, selectivity, and reversibility of apoptotic execution.
| Caspase | Type | Activation Platform | Key Substrates / Role | Disease Relevance |
|---|---|---|---|---|
| Caspase-1 | Inflammatory | Inflammasome (NLRP3, NLRP1, AIM2, NLRC4) | Pro-IL-1β, pro-IL-18 cleavage; GSDMD (pyroptosis) | Inflammatory disease; pyroptosis in infection, autoinflammatory syndromes |
| Caspase-2 | Initiator | PIDDosome (PIDD-RAIDD platform) | Activated by DNA damage, metabolic stress; cleavage of Golgi protein GRASP65, BID | Tumour suppression; metabolic disease |
| Caspase-3 | Executioner | Cleaved by caspases -8, -9, -10 | ICAD (releases CAD → DNA ladder); PARP-1; lamins; gelsolin; focal adhesion kinase; >600 substrates | Central executioner; absent/mutated in some cancers; neurodegeneration target |
| Caspase-6 | Executioner | Cleaved by caspase-3 | Lamins A/B/C (nuclear collapse); huntingtin cleavage generates toxic N-terminal fragment | Huntington’s disease; neuronal apoptosis |
| Caspase-7 | Executioner | Cleaved by caspases -8, -9 | Overlaps with caspase-3; contributes to ER stress apoptosis; PARP cleavage | Redundant with caspase-3 in most contexts; independent role in anoikis |
| Caspase-8 | Initiator | DISC (Fas, TRAIL-R1/R2, TNFR1-complex II) | BID→tBID (amplification); direct caspase-3/7 activation; RIPK1/RIPK3 cleavage (blocks necroptosis) | Frequently silenced in cancer (methylation); protects against necroptosis |
| Caspase-9 | Initiator | Apoptosome (Apaf-1/cytochrome c) | Caspase-3, -6, -7 activation; substrate of caspase-3 (positive feedback) | Intrinsic pathway initiator; XIAP-regulated; therapeutic target in resistance |
| Caspase-11 (mouse) / -4, -5 (human) | Inflammatory | Direct LPS (lipopolysaccharide) binding | GSDMD cleavage → pyroptosis; non-canonical inflammasome | Gram-negative sepsis; inflammatory bowel disease |
Number of caspase-3 substrates identified in human cells — making caspase-3 the most prolific known protease in terms of biological substrate diversity
Caspase-3’s promiscuous substrate cleavage reflects the systematic nature of apoptotic disassembly — it must simultaneously collapse the cytoskeleton, package chromatin into apoptotic bodies, disable DNA repair, stop transcription and translation, and signal for phagocytic clearance. The breadth of caspase-3 activity also underlies the challenge of developing specific caspase inhibitors: pan-caspase inhibitors such as Z-VAD-FMK (zVAD) block all caspase activity and are used experimentally but would have profound physiological consequences (blocking immunity, development, tissue homeostasis) if administered chronically in vivo. Selective caspase inhibition for specific therapeutic applications — blocking caspase-1 in inflammatory disease, caspase-9 in ischaemia — remains an active area of drug development.
p53 — Guardian of the Genome and Master of the Apoptotic Decision
p53 (encoded by the TP53 gene on chromosome 17p13) is the most studied protein in cancer biology and one of the most important regulatory proteins in all of cell biology — a transcription factor that sits at the intersection of DNA damage sensing, cell cycle control, and apoptosis induction. It is often called the “guardian of the genome” for its role in sensing genomic damage and deciding between repair and elimination of the damaged cell.
p53 — From DNA Damage Sensor to Apoptosis Inducer
Under undamaged conditions, p53 protein is kept at very low levels through a continuous cycle of synthesis and rapid MDM2-mediated ubiquitination and proteasomal degradation. MDM2 is a RING-domain E3 ubiquitin ligase that binds the N-terminal transactivation domain of p53 — this interaction is the therapeutic target of nutlin-class MDM2 inhibitors. DNA double-strand breaks activate ATM kinase; ssDNA and replication stress activate ATR; both phosphorylate p53 at Ser15 and indirectly at Ser20 (via CHK1/CHK2), disrupting the p53-MDM2 interaction and allowing p53 accumulation. Oncogenic activation (MYC, RAS amplification) triggers ARF protein expression, which sequesters MDM2 and also causes p53 accumulation. Post-translational modifications (acetylation, methylation, sumoylation) at multiple sites further modulate p53 activity and transcriptional target selection.
Accumulated p53 acts as a sequence-specific transcription factor, inducing target genes through p53 response elements (two decameric half-sites RRRCWWGYYY separated by 0–13 bp). The apoptotic transcriptional targets include: PUMA (p53 upregulated modulator of apoptosis) — a potent BH3-only direct activator of BAX/BAK; NOXA — a BH3-only protein that neutralises MCL-1; BAX itself; APAF-1 (apoptosome scaffold); Fas/CD95 (connecting to extrinsic pathway); DR5/TRAIL-R2; and PIDD (activates caspase-2 via PIDDosome). Cell cycle arrest targets include p21/CDKN1A (CDK inhibitor), GADD45, and MDM2 (negative feedback). The critical question — why p53 induces arrest in some contexts and apoptosis in others — involves the relative expression of survival factors (BCL-2, BCL-XL), the severity and persistence of damage, cell type, and the identity of p53 co-factors (ASPP proteins promote apoptotic gene selection; iASPP inhibits it).
IAPs, SMAC, and the Survival Checkpoint Within the Execution Phase
Even after MOMP and cytochrome c release, a final checkpoint exists before executioner caspase activation is complete: the inhibitor of apoptosis proteins (IAPs). IAPs are a family of eight proteins in humans (XIAP, cIAP1, cIAP2, BIRC2, BIRC3, BIRC5/survivin, BIRC7, BIRC8) that contain BIR (baculoviral IAP repeat) domains that directly bind and inhibit active caspases. Understanding IAPs is critical both for understanding how cells survive near-death stress and for developing anti-cancer IAP inhibitors (SMAC mimetics).
Efferocytosis — Silent Disposal of Dying Cells
Apoptosis without efficient clearance of the resulting debris would be catastrophically inflammatory — apoptotic cells undergoing secondary necrosis would release their pro-inflammatory contents, DAMPs, and autoantigens, triggering the very inflammatory responses that apoptosis is designed to avoid. Efferocytosis — the phagocytic engulfment and digestion of apoptotic cells — is therefore an integral component of apoptosis as a biological process, not merely its aftermath.
Efferocytosis is not passive garbage collection — it is active immunological instruction. Every apoptotic cell that is engulfed teaches the phagocyte that this is a normal, non-threatening event, and the phagocyte responds by producing anti-inflammatory mediators that maintain tissue homeostasis and prevent autoimmunity.
Reflecting the literature on efferocytosis and anti-inflammatory immunological programming, including TGF-β and IL-10 secretion from macrophages that have engulfed apoptotic cells
In systemic lupus erythematosus, defective efferocytosis — caused by complement deficiency, reduced MFG-E8, or impaired MER tyrosine kinase signalling — allows apoptotic cells to accumulate and undergo secondary necrosis, releasing nuclear autoantigens (DNA, histones, Ro/La) that drive the anti-nuclear antibody response central to SLE pathogenesis.
Reflecting the established link between efferocytosis defects and autoimmune disease pathogenesis, particularly in SLE where complement C1q and C4 deficiencies are the strongest genetic risk factors
Apoptosis in Development, Tissue Homeostasis, and Immunity
The physiological functions of apoptosis extend far beyond eliminating damaged cells — it is an active morphogenetic tool deployed with precision timing during embryonic development, an essential regulator of tissue size in adults, and a critical mechanism for immune system education and homeostasis.
Embryonic Morphogenesis — Sculpting Form Through Deletion
Apoptosis shapes embryonic structures by eliminating excess cells that would otherwise obstruct or misfold the developing form. Interdigital cell death eliminates the webbing between future fingers and toes (absent in syndactyly mutations affecting Bmpr1a or BMP4/7 signalling). The mammalian kidney tubular system forms from solid cell cords that become hollow tubes through apoptotic removal of the interior cells. Neural tube closure requires apoptosis to eliminate excess cells at the fusing edges; failure causes neural tube defects. In the nervous system, approximately half of all neurons generated during development are eliminated by apoptosis through Darwinian-like competition for limiting neurotrophic survival factors — neurons that fail to innervate their target tissue and receive sufficient NGF, BDNF, or NT-3 undergo apoptosis through the default intrinsic pathway.
Thymic Selection — Educating the T Cell Repertoire
The thymus eliminates T cells that would cause autoimmunity through two apoptotic selection processes. Positive selection (in the thymic cortex) deletes T cells whose T cell receptors cannot interact with self-MHC molecules — they die by “neglect” through apoptosis driven by growth factor withdrawal and BIM upregulation. Approximately 97% of developing thymocytes die by apoptosis during thymic selection — an astonishing level of programmed attrition that ensures only useful T cells (those that can recognise foreign peptide presented by self-MHC) emerge into the periphery. Negative selection (in the thymic medulla and cortex) deletes T cells whose receptors bind self-peptide:self-MHC too strongly — eliminating potentially autoreactive T cells through Bim-dependent, p53-independent apoptosis. AIRE (autoimmune regulator) protein in medullary thymic epithelial cells enables expression of tissue-specific antigens (insulin, thyroglobulin) in the thymus for negative selection — AIRE mutations cause autoimmune polyendocrinopathy.
CTL/NK Cell Killing — Perforin-Granzyme Pathway
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells kill target cells (virus-infected cells, cancer cells, transplanted cells) by inducing apoptosis through two mechanisms. The perforin-granzyme pathway: lytic granules containing perforin and granzymes (serine proteases — primarily granzymes A and B) are directionally secreted into the immunological synapse. Perforin forms pores in the target cell membrane; granzyme B enters the target cell through these pores (or via mannose-6-phosphate receptor endocytosis) and directly cleaves caspase-3 and BID, activating apoptosis. The Fas-FasL pathway: activated CTLs express FasL that binds Fas on target cells, initiating DISC formation and caspase-8 activation as described above. Genetic defects in perforin (familial haemophagocytic lymphohistiocytosis, FHL) or in the granule secretion machinery (Griscelli syndrome, Chediak-Higashi syndrome) cause fatal inflammatory syndromes due to inability to terminate immune activation through CTL killing of activated macrophages.
Activation-Induced Cell Death (AICD) — Immune Contraction
Following antigen clearance, the expanded population of antigen-specific T and B cells must be deleted to restore immune homeostasis and prevent chronic immune activation — a process called clonal contraction. Activation-induced cell death (AICD) occurs when repeatedly stimulated T cells upregulate both Fas and FasL, leading to fratricide (FasL on one T cell activating Fas on another) and autocrine (self) killing. The magnitude and duration of TCR signalling, co-stimulation strength, and cytokine milieu determine whether T cells undergo AICD or survive to form memory. The BCL-2 family plays a critical role in survival vs. death at this phase: IL-7-mediated MCL-1 and BCL-2 expression is required for transition to memory cells; cytokine withdrawal leads to BIM upregulation and AICD of short-lived effectors.
Gut Epithelial Turnover — Apoptosis in Self-Renewing Tissues
The intestinal epithelium — the body’s most rapidly self-renewing tissue — turns over completely every 3–5 days, with stem cells in the crypts generating ~10⁸ cells daily that migrate upward along the villus and are shed from the villus tip by anoikis (apoptosis triggered by loss of integrin-mediated adhesion). This continuous apoptotic shedding matches proliferation at the crypt base, maintaining gut homeostasis. Disruption of this balance — by inflammatory bowel disease reducing crypt survival, or by epithelial dysplasia suppressing villus tip apoptosis — shifts the cell number set-point. Colorectal cancer cells frequently suppress anoikis through FAK (focal adhesion kinase) amplification and BCL-2/BCL-XL overexpression, enabling survival in suspension and subsequent metastatic colonisation of distant tissues.
Apoptosis Evasion in Cancer — the Hallmark of Tumour Survival
The evasion of apoptosis is one of the defining capabilities of cancer cells — listed as one of the six original hallmarks of cancer by Hanahan and Weinberg in their influential 2000 Cell paper and retained in the updated 2011 framework. Cancer cells acquire apoptosis resistance through multiple converging mechanisms that target every level of the apoptotic machinery, and this resistance underlies both the uncontrolled accumulation of cancer cells and their resistance to chemotherapy and radiotherapy. As thoroughly examined in the PMC systematic review of apoptosis and cancer: should apoptosis be the ultimate therapy target, overcoming apoptosis resistance is one of the central challenges in oncology.
Frequency of specific apoptosis evasion mechanisms in human cancers (approximate relative prevalence — schematic)
Apoptosis in Neurodegeneration, Ischaemia, and Inflammatory Disease
While cancer represents excessive suppression of apoptosis, many other diseases reflect the opposite problem — excessive or inappropriate apoptosis eliminating cells that are needed. In these conditions, neurons, cardiomyocytes, hepatocytes, or immune cells are lost through apoptotic pathways that are inappropriately activated by disease-specific triggers, and therapeutic inhibition of apoptosis is a rational strategy.
Amyloid-β, Tau, and Neuronal Apoptosis
Amyloid-β oligomers (the most neurotoxic species in AD, distinct from fibrillar plaques) activate caspase-3 and -9 in hippocampal and cortical neurons through multiple mechanisms: oxidative stress causing mitochondrial dysfunction and cytochrome c release; ER stress activating PERK/ATF4/CHOP axis and BIK; and NMDA receptor overactivation causing calcium influx that activates calpain proteases which cleave and activate caspase-3. Tau is a substrate of caspase-3: cleavage at Asp421 generates a truncated fragment (Tau-Asp421) that accelerates microtubule dissociation and tau aggregation, potentially propagating pathology. p53 levels are elevated in AD neurons; synaptic loss (before overt neuronal death) correlates with caspase-3 activation at synapses.
Dopaminergic Neuron Loss via Mitochondrial Apoptosis
Selective loss of dopaminergic neurons in the substantia nigra pars compacta involves mitochondrial dysfunction and intrinsic pathway activation. Mutations in PINK1 (PARK6) and PARKIN (PARK2) impair mitophagy — the selective autophagy of dysfunctional mitochondria — causing accumulation of depolarised mitochondria that release cytochrome c and undergo MOMP. α-Synuclein aggregates (Lewy bodies) directly permeabilise mitochondrial membranes and inhibit complex I of the respiratory chain, generating reactive oxygen species and mitochondrial stress. Dopaminergic neurons are particularly vulnerable because of their high metabolic demands, extensive axonal arborisations (requiring sustained mitochondrial energy delivery), and neuromelanin-mediated iron accumulation generating oxidative stress.
Penumbral Apoptosis After ATP Depletion
Cerebral ischaemia produces two zones of injury: the infarct core (where neurons die within minutes by acute ATP depletion and necrosis) and the penumbra (where partial perfusion is maintained for hours, allowing apoptosis to proceed). In the penumbra, glutamate excitotoxicity (NMDA receptor over-activation, calcium influx), oxidative stress, and mitochondrial dysfunction activate intrinsic apoptosis. Caspase-3 inhibitors (z-DEVD-FMK) or Bcl-2 overexpression reduce penumbral neuronal loss in experimental stroke models. The therapeutic window for penumbral salvage (up to 6–24 hours depending on imaging selection) has driven development of neuroprotective strategies targeting apoptosis, though translation to clinical efficacy has been challenging.
CD4+ T Cell Depletion by Indirect Apoptosis
HIV destroys CD4+ T cells not only by direct viral cytopathic effects but by triggering apoptosis through multiple indirect mechanisms. Bystander apoptosis: uninfected CD4+ T cells are killed by soluble HIV envelope glycoprotein gp120 binding CXCR4, activating intrinsic apoptosis through a caspase-dependent pathway. Pyroptosis: abortively infected CD4+ T cells in lymph nodes undergo caspase-1-mediated pyroptotic cell death (not apoptosis) — a highly inflammatory form of death that paradoxically fuels the local inflammatory environment and recruits more target cells. Direct viral killing: productively infected T cells die through viral cytopathic effects including intracellular protein overload, ER stress, and Vpr-induced cell cycle arrest in G2 phase followed by apoptosis.
Hepatocyte Apoptosis in NAFLD and Viral Hepatitis
The liver is uniquely sensitive to Fas-mediated apoptosis — hepatocytes are type II cells dependent on the BID cleavage amplification loop for sufficient apoptotic execution. Fas/FasL interactions drive hepatocyte apoptosis in autoimmune hepatitis, viral hepatitis (where CTLs kill infected hepatocytes via perforin/granzyme and FasL), and drug-induced liver injury. In non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), hepatocyte lipotoxicity activates intrinsic apoptosis through ER stress-induced PUMA and NOXA upregulation and saturated fatty acid-induced JNK activation targeting BIM. Apoptotic hepatocytes release HMGB1 (a DAMP) and caspase-1 activating danger signals that recruit and activate Kupffer cells, driving the inflammation-fibrosis axis of NAFLD progression to cirrhosis.
Too Little Apoptosis Allows Self-Reactive Cells to Survive
Failure of apoptotic elimination of autoreactive lymphocytes causes systemic autoimmune disease. SLE (systemic lupus erythematosus): impaired efferocytosis and defective FasL-Fas-mediated lymphocyte deletion allow accumulation of nuclear debris and survival of anti-nuclear autoimmune clones. ALPS (autoimmune lymphoproliferative syndrome): germline mutations in Fas, FasL, or caspase-10 impair AICD and cause massive lymphadenopathy, autoimmune cytopaenias, and lymphoma predisposition. Rheumatoid arthritis: synovial fibroblast resistance to Fas-mediated apoptosis (through cFLIP overexpression, PTEN mutation causing AKT-driven BCL-2 survival) enables their pathological survival and cartilage invasion. Therapeutic targeting of apoptosis defects in synoviocytes is an active area in RA drug development.
Therapeutic Targeting of Apoptotic Pathways — Drugs, Trials, and Principles
The dual role of apoptosis dysregulation — too little in cancer, too much in neurodegeneration and ischaemia — creates opposing therapeutic opportunities: pro-apoptotic drugs for cancer and anti-apoptotic drugs for degenerative and inflammatory conditions. The cancer application has advanced furthest, with the first approved apoptosis-targeted therapy (venetoclax) transforming treatment of leukaemia and establishing the BH3 mimetic class as one of the most successful targeted therapy conceptual advances in oncology.
BCL-2 Inhibitor (FDA Approved)
BH3 mimetic selective for BCL-2 (Ki ~0.01 nM). Approved for CLL (with obinutuzumab or alone in relapsed/refractory), AML (with azacitidine), and multiple myeloma (combinations). Causes rapid lysis of BCL-2-dependent tumour cells. Major toxicity: tumour lysis syndrome (rapid cell death releasing potassium and uric acid) and neutropenia.
BCL-2/BCL-XL Inhibitor (Clinical Trials)
Inhibits both BCL-2 and BCL-XL (Ki ~1 nM each). Active in lymphoma and some solid tumours. Dose-limiting thrombocytopenia from BCL-XL inhibition in platelets (BCL-XL is the dominant platelet survival factor). Platelet-sparing combinations with venetoclax and platelet-targeted delivery strategies under investigation.
IAP Antagonists (Multiple Clinical Trials)
Bivalent (LCL-161, AEG40826) and monovalent (GDC-0152) small molecules mimicking the AVPI IBM of SMAC, binding BIR2/BIR3 of XIAP and inducing autoubiquitination-degradation of cIAP1/2. Sensitise cancer cells to TRAIL, TNF, and chemotherapy. TNF-mediated killing a key mechanism; responses correlate with TNF inducibility in patient tumours.
p53 Activators (Clinical Development)
Nutlins (idasanutlin, AMG-232, siremadlin) bind MDM2 hydrophobic cleft, displacing p53 and allowing its accumulation in tumours with wild-type TP53 (30–50% of cancers). Activate p53-mediated PUMA/NOXA induction and cell cycle arrest. Limited by myelosuppression and nausea. Combination with venetoclax in AML is in Phase 2 trials.
Emerging Class (Phase 1/2)
AMG-176, S63845, AZD5991 — selective MCL-1 BH3 mimetics in Phase 1/2 trials for haematological malignancies. MCL-1 is the dominant resistance mechanism to venetoclax; MCL-1 inhibitor combinations with venetoclax show synergistic activity in AML and myeloma. Cardiac safety (MCL-1 maintains cardiomyocyte mitochondrial function) is under careful evaluation.
Neuroprotection and Liver Disease (Trials)
Emricasan (pan-caspase inhibitor) reduced liver inflammation in NASH and cirrhosis in Phase 2 but did not meet primary endpoint in Phase 2b. IDN-6556 (a related compound) showed liver histological improvement. Neuroprotective caspase inhibition after ischaemia/traumatic brain injury remains under investigation in preclinical models. Challenge: on-target immune suppression from blocking inflammatory caspases.
Detecting Apoptosis — Laboratory Methods and Their Principles
Identifying and quantifying apoptosis in experimental or clinical samples requires methods that detect its specific morphological, biochemical, or molecular features with sufficient sensitivity and specificity to distinguish it from necrosis, autophagy, and mitotic arrest. The choice of method depends on whether single-cell or population-level data are needed, whether live-cell kinetic measurements are required, and the specific pathway component being interrogated.
Annexin V / PI Dual Staining — Gold Standard Flow Cytometric Method
PS exposure on the outer membrane leaflet is detected by annexin V (which binds PS with high affinity in the presence of calcium). Propidium iodide (PI) or 7-AAD is co-used as a membrane integrity dye — excluded from intact cells. Annexin V+/PI− cells are early apoptotic (PS exposed, intact membrane); Annexin V+/PI+ cells are late apoptotic/secondary necrotic (PS exposed, membrane permeabilised); Annexin V−/PI− cells are viable; Annexin V−/PI+ cells are primary necrotic or damaged. This four-quadrant analysis provides a complete picture of the death status of a cell population. Can be performed with live cells in real-time and on suspension or adherent cells released by trypsin. Limitation: trypsinisation itself can induce PS exposure; suspension must be gentle.
TUNEL and DNA Ladder — DNA Fragmentation Assays
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) labels the 3′-OH ends of DNA fragments generated by caspase-activated DNase (CAD) in apoptotic nuclei. TdT enzyme incorporates labelled dUTP at these nicks; the incorporated label is detected fluorescently (for flow or microscopy) or colorimetrically (for histochemistry). Highly specific for apoptosis when used with morphological confirmation. DNA laddering detects the ~180 bp internucleosomal fragments on agarose gel electrophoresis — simple and cheap but requires high numbers of apoptotic cells (not sensitive). Sub-G1 fraction flow cytometry detects cells with fractional DNA content (below the G1 2N peak) caused by DNA fragmentation — sensitive but requires ethanol fixation and cannot distinguish early from late apoptosis.
Caspase Activity, PARP Cleavage, and Mitochondrial Assays
Caspase-3/7 activity: fluorogenic substrates (Ac-DEVD-AMC for caspase-3/7; Ac-IETD-AFC for caspase-8; Ac-LEHD-AFC for caspase-9) release fluorescent leaving groups upon cleavage — measured in cell lysates or detected in intact cells by cell-permeable reagents (CellEvent Caspase-3/7 Green). PARP cleavage: western blot detection of the 89 kDa (from 116 kDa intact) cleaved PARP fragment using the Cell Signaling Technology cleaved PARP D214 antibody is a standard apoptosis readout in most cell biology labs. JC-1 or TMRE staining: detects loss of mitochondrial membrane potential (ΔΨm), a consequence of MOMP, by flow cytometry — red-to-green shift of JC-1 fluorescence indicates depolarisation. Cytochrome c immunofluorescence: diffuse cytosolic staining vs. punctate mitochondrial localisation distinguishes cells that have or have not undergone MOMP.
Expert Cell Biology & Biomedical Science Academic Support
From cell death pathway diagrams and caspase cascade problem sets to cancer biology essays on Bcl-2 family proteins, biomedical lab reports, and doctoral dissertations on apoptosis in disease — specialist molecular biology and biomedical science writers cover every aspect of programmed cell death.
Frequently Asked Questions About Apoptosis
Extend your studies: biology assignments · science writing · biology research papers · nursing assignments · lab reports · literature reviews · dissertations · chemistry homework · complex scientific assignments · public health · critical analysis · research papers · citation and referencing · challenging research topics · capstone projects · anatomy & physiology
